reports
Sunrun Inc: 1 director
A director at Sunrun Inc sold 50,000 shares at 18.595USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Sunrun Builds the Nation’s Largest Distributed Power Plant After Quint...
Sunrun Builds the Nation’s Largest Distributed Power Plant After Quintupling Customer Participation in 2025 Sunrun scales the nation’s largest distributed power plant with 400% growth, 17 programs, major partnerships, and record grid dispatches as AI-driven electricity demand surges SAN FRANCISCO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- With rising electricity costs, growing risk of power outages, and a widening gap between power supply and demand, Sunrun (Nasdaq: RUN), America’s largest provider of home battery storage, solar, and home-to-grid power plants, rapidly delivered new, dispatchabl...
Lexicon Announces Pricing of Approximately $94.6 Million Public Offeri...
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $1.30 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering a...
Lexicon Announces Proposed Public Offering of Common Stock
Lexicon Announces Proposed Public Offering of Common Stock THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the p...
Sunrun Announces Date for Fourth Quarter and Full-year 2025 Earnings R...
Sunrun Announces Date for Fourth Quarter and Full-year 2025 Earnings Report Earnings Release and Conference Call Scheduled for February 26, 2026 SAN FRANCISCO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN) today announced that it will issue its fourth quarter and full-year 2025 earnings report after the market closes on Thursday, February 26, 2026. A conference call has been scheduled to discuss these earnings results at 1:30 p.m. Pacific Time. The conference call can be accessed live via the Sunrun Investor Relations website at or over the phone by dialing (877) 407-5989 (to...
Frequency Electronics Inc. Announces a contract award valued at approx...
Frequency Electronics Inc. Announces a contract award valued at approximately $6.0 million MITCHEL FIELD, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM), a leading provider of precision timing and frequency control products for space and terrestrial applications, is pleased to announce the follow-on award of several contracts from a major aerospace company for precision “g” (acceleration) compensated Oven-controlled Quartz Oscillators (OCXO) for ultimate application in US Government software-defined radio systems. These precision...
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27,...
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026. The event will commemorate Lexicon’s 30th anniversary as a biopharmaceutical company building a differentiated pipeline of oral small-molecule therapies for people living with serious cardiometabolic diseases and chronic neuropathic pain. “In its early days, Lexicon was focused on pioneering a deeper understa...
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting wi...
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain – No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in diabetic peripheral neuropathic pain (DPNP). During the ...
Upwork to Report Fourth Quarter and Full Year 2025 Financial Results o...
Upwork to Report Fourth Quarter and Full Year 2025 Financial Results on February 9, 2026 PALO ALTO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: UPWK), the world’s human and AI-powered work marketplace, today announced that it will report its financial results for the fourth quarter and full year of 2025 on Monday, February 9, 2026 after market close. The company will host a Q&A conference call to discuss these results at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on the same day. A live webcast of the call will be available on the Upwork Investor Relations website at . An a...
FEI-Zyfer Announces Contract Awards for Approximately $6.0 Million
FEI-Zyfer Announces Contract Awards for Approximately $6.0 Million Garden Grove, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- FEI-Zyfer, Inc., a wholly-owned subsidiary of Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM), a leading provider of precision timing and frequency control products, is pleased to announce the receipt of contracts totaling approximately $6.0 million in two of our core business areas for Assured-PNT (Position Navigation and Timing) – for secure communications systems and for time, frequency, and synchronization distribution systems in support of airb...
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the...
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on track for NDA resubmission and potential approval in 2026 Company presentation January 15 at 12:00 p.m. PT (3:00 p.m. ET) THE WOODLANDS, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a business and pipeline update at...
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access...
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” -White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers to support millions of Americans suffering from chronic pain- THE WOODLANDS, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- In October 2025, (Nasdaq: LXRX) convened an in-person Roundtable in Washington, D.C., to better understand the unmet needs of people living with chronic pain and id...
Upwork December Monthly Hiring Report: Operational Roles Rise as Busin...
Upwork December Monthly Hiring Report: Operational Roles Rise as Businesses Brace for Macro Uncertainty in 2026 Rising demand for project management and accounting show companies shifting from experimentation to execution PALO ALTO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: UPWK), the world’s human and AI-powered work marketplace, today released its , revealing a clear shift toward hiring focused on operational execution as businesses prepare for a potentially volatile start to 2026. The report draws from more than 1 million job posts in the U.S. on the Upwork Marketplace annu...
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Heal...
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 12:00 p.m. PT (3:00 p.m. ET) in San Francisco. The live event and replay of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ live...
Frequency Electronics Inc. Awarded Contract for Geostationary Satellit...
Frequency Electronics Inc. Awarded Contract for Geostationary Satellite Constellation MITCHEL FIELD, N.Y., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM), a leading provider of precision timing and frequency control products for space and terrestrial applications, is pleased to announce that it has been awarded a significant contract to provide precision time and frequency systems for a geostationary environmental satellite program. This contract is valued at approximately $9.2 million. It includes oscillators, frequency distribution ...
Frequency Electronics, Inc. Announces Second Quarter and Fiscal Year 2...
Frequency Electronics, Inc. Announces Second Quarter and Fiscal Year 2026 Financial Results MITCHEL FIELD, N.Y., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is pleased to announce its financial results for the second quarter and fiscal year 2026. Revenue for the three and six months ended October 31, 2025, was approximately $17.1 million and $30.9 million, respectively, compared to $15.8 million and $30.9 million, respectively, reported for the same period of fiscal year 2025. Operating income for the three and six months ended Oct...
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in t...
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The paper, titled “Acyl-CoA Synthetase 5 knockout and inhibitors protect against diet-induced obesity in mice by activating the ileal brake,” was published online in the . ACSL5 is an enz...
Frequency Electronics Announces Second Quarter Fiscal 2026 Financial R...
Frequency Electronics Announces Second Quarter Fiscal 2026 Financial Results Conference Call: Thursday, December 11, 2025, at 4:30 PM ET MITCHEL FIELD, N.Y., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (NASDAQ: FEIM), will hold a conference call to discuss results for the second quarter of its fiscal year 2026, ended October 31, 2025, on Thursday, December 11, 2025, at 4:30 PM Eastern Time. This call is being webcast by Issuer Direct Corporation and can be accessed in the Investor Relations section of Frequency’s web site at . Investors and analysts may also access the...
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in No...
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025, at the Mayflower Hotel in Washington, D.C. This data is from SOTA-P-CARDIA, a prospective, randomized, double-...
Upwork November Monthly Hiring Report: Demand Rose for Quality Assuran...
Upwork November Monthly Hiring Report: Demand Rose for Quality Assurance Testers, Interpreters, and Creatives Companies turn to independent professionals to power digital operations with human touch, but skill gaps loom as a top challenge for 39% of businesses heading into 20261 PALO ALTO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: UPWK), the world’s human and AI-powered work marketplace, today released its Monthly Hiring Report for November, finding that amid the race to scale AI systems, demand is rising for human-centered skills to reinforce work quality, uplevel communicati...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.